Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Arbutus Biopharma CorporationNASDAQ: ABUS
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $11K fell 99.9% year over year, in line with the -99.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.0% from the prior quarter.
Context
- Cost of revenue amounted to 2.6% of revenue in FY2025, up 2.6 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -99.9% toward the trailing-twelve-month pace of -99.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 363K USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 363K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 cost of revenue of $33K is the 8th highest of the 9 companies compared; the peer median is $1.5M.
- Its year-over-year change of -99.8% is the 5th highest of 6, against a peer median of -36.4%.
- Cost of revenue amounts to 0.0% of revenue for ABUS, versus a peer median of 21.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $974.34M | +141.9% | +58.9% | 20.3% | |
| LTM Mar 2026 | $40.76M | +72.9% | — | — | |
| LTM Mar 2026 | $16.18M | -62.1% | -87.7% | 22.8% | |
| LTM Sep 2026 | $1.8M | — | -47.6% | 0.4% | |
| LTM Mar 2026 | $1.21M | — | — | 1.7% | |
| LTM Mar 2026 | $309.37K | — | -73.0% | 33.6% | |
| LTM Mar 2026 | $119K | -36.4% | — | — | |
| LTM Mar 2026 | $33K | -99.8% | — | 0.0% | |
| LTM Mar 2026 | -$114.78M | -122.6% | -73.4% | 175.2% | |
| Peer median (excluding ABUS) | $1.5M | -36.4% | -73.0% | 21.5% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.99M | 39.02M | 18.14M | 6.17M | 14.08M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 363K |
| Gross Profit | 10.99M | 39.02M | 18.14M | 6.17M | 13.72M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% |
| Research & Development | 65.5M | 84.41M | 73.7M | 54.04M | 25.24M |
| Selling, General & Admin | 17.14M | 17.83M | 22.48M | 22.11M | 15.89M |
| Operating Expenses | 84.51M | 104.48M | 96.24M | 82.49M | 40.77M |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| EBITDA | (71.64M) | (61.86M) | (70.99M) | (68.4M) | (33.04M) |
| EBITDA Margin | -652.0% | -158.5% | -391.3% | -1108.5% | -234.6% |
| Operating Income | (73.52M) | (65.46M) | (78.1M) | (76.32M) | (27.05M) |
| Operating Margin | -669.1% | -167.8% | -430.5% | -1236.7% | -192.1% |
| Interest Income | 127K | 2.19M | 5.69M | 6.59M | 4.07M |
| Interest Expense | 2.86M | 1.73M | 459K | 137K | 97K |
| Other Income / Expenses | (2.73M) | 444K | 5.25M | 6.4M | (6.45M) |
| Income Before Tax | (76.25M) | (65.01M) | (72.85M) | (69.92M) | (33.5M) |
| Pre-Tax Margin | -693.9% | -166.6% | -401.6% | -1133.0% | -237.9% |
| Income Tax Expense | 0 | 4.44M | 0 | 0 | 0 |
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Net Margin | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| EPS (Basic) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| EPS (Diluted) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| Weighted Avg Shares | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
| Weighted Avg Shares (Diluted) | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.